Skip to main content

Advertisement

SpringerLink
Log in

Do CSF levels of t-Tau, p-Tau and β1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

An Erratum to this article was published on 19 September 2014

Abstract

Purpose

To investigate the relationships among cerebrospinal fluid (CSF) levels of t-Tau, p-Tau and Aβ1-42 amyloid peptide and 123I-FP-CIT uptake.

Methods

The study included 58 subjects (31 men and 27 women, age 67 ± 9 years) with a clinical diagnosis of Parkinson disease diagnosed according to the United Kingdom Parkinson Disease Society Brain Bank criteria. All subjects underwent a CSF assay 28 ± 3 days before 123I-FP-CIT SPECT scanning. The relationships were evaluated by means of linear regression analysis and Pearson correlation.

Results

Striatal 123I-FP-CIT was positively related to both t-Tau and p-Tau CSF values with low levels of t-Tau and p-Tau being related to a low uptake of 123I-FP-CIT. In particular, differences with higher statistical significance were found for the striatum between the contralateral side and the side mainly affected on clinical examination (P < 0.001). No significant relationships were found between Aβ1-42 amyloid peptide and 123I-FP-CIT binding.

Conclusion

The results of our study suggest that the presynaptic dopaminergic system is more involved in Parkinson disease patients with lower t-Tau and p-Tau CSF values while values of Aβ1-42 amyloid peptide seems not to be related to nigrostriatal degeneration in our series.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Schillaci O, Chiaravalloti A, Pierantozzi M, Di Pietro B, Koch G, Bruni C, et al. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson’s disease at the early stages: molecular imaging with 123I-FP-CIT SPECT. Int J Mol Med. 2011;28:881–6.

    PubMed  CAS  Google Scholar 

  2. Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. J Neurol Neurosurg Psychiatry. 2013;84:774–83.

    Article  PubMed  Google Scholar 

  3. Chiaravalloti A, Stefani A, Di Biagio D, Pierantozzi M, Tavolozza M, Di Pietro B, et al. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson’s disease. Ann Nucl Med. 2013;27:444–51.

    Article  PubMed  Google Scholar 

  4. Halliday G, Lees A, Stern M. Milestones in Parkinson’s disease – clinical and pathologic features. Mov Disord. 2011;26:1015–21.

    Article  PubMed  Google Scholar 

  5. Playford ED, Brooks DJ. In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc Brain Metab Rev. 1992;4:144–71.

    PubMed  CAS  Google Scholar 

  6. Treglia G, Cason E, Cortelli P, Gabellini A, Liguori R, Bagnato A, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques? J Neuroimaging. 2014;24:149–54.

    Article  PubMed  Google Scholar 

  7. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement. 2014. doi:10.1016/j.jalz.2014.02.004.

    Google Scholar 

  8. Tamaoka A, Sawamura N, Odaka A, Suzuki N, Mizusawa H, Shoji S, et al. Amyloid beta protein 1-42/43 (A beta 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res. 1995;679:151–6.

    Article  PubMed  CAS  Google Scholar 

  9. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI. Tau protein: relevance to Parkinson’s disease. Int J Biochem Cell Biol. 2010;42:1775–8.

    Article  PubMed  CAS  Google Scholar 

  10. Medina M, Avila J. The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci. 2014;8:113.

    PubMed  PubMed Central  Google Scholar 

  11. Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998;19:109–16.

  12. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013;70:1277–87.

    PubMed  PubMed Central  Google Scholar 

  13. Attems J, Quass M, Jellinger KA. Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol. 2007;113:53–62.

    Article  PubMed  CAS  Google Scholar 

  14. Hughes A, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;66:181–4.

    Article  Google Scholar 

  15. Fahn S, Elton RL, Committee motUD. Unified Parkinson’s disease rating scale. Florhan Park HJ: Macmillan Healthcare Information; 1987

  16. Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, et al. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int. 2011;2011:246412.

    PubMed  PubMed Central  Google Scholar 

  17. Dickson JC, Tossici-Bolt L, Sera T, de Nijs R, Booij J, Bagnara MC, et al. Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging. 2012;39:188–97.

    Article  PubMed  Google Scholar 

  18. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using 123I-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging. 2002;29:BP30–5.

    Article  PubMed  CAS  Google Scholar 

  19. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978:25:638–43.

    Article  Google Scholar 

  20. Schillaci O, Chiaravalloti A, Travascio L, Floris R, Simonetti G. F-FDG PET/MR in herpes simplex virus encephalitis: A case study. Rev Esp Med Nucl Imagen Mol. 2014. doi:10.1016/j.remn.2013.10.002.

    Google Scholar 

  21. Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with (123)I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2005;32:1452–6.

    Article  PubMed  CAS  Google Scholar 

  22. Chiaravalloti A, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123–32.

    PubMed  CAS  Google Scholar 

  23. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc. 2007;82:591–605.

    Article  PubMed  Google Scholar 

  24. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.

    Google Scholar 

  25. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease. Neurobiol Aging. 2007;28:742–7.

    Article  PubMed  CAS  Google Scholar 

  26. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, et al. CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord. 2010;25:2682–5.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69:570–80.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson’s disease and in dementia with Lewy bodies. Brain Res. 1999;843:53–61.

    Article  PubMed  CAS  Google Scholar 

  29. Muntane G, Dalfo E, Martinez A, Ferrer I. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related alpha-synucleinopathies. Neuroscience. 2008;152:913–23.

    Article  PubMed  CAS  Google Scholar 

  30. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44.

    Article  PubMed  CAS  Google Scholar 

  31. Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84:1288–95.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain. 2010;133:713–26.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129:526–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133, Rome, Italy

    Agostino Chiaravalloti, Alessandro Fiorentini, Annamaria Lacanfora & Orazio Schillaci

  2. Department of Neurosciences, University Tor Vergata, Rome, Italy

    Alessandro Stefani & Paolo Stanzione

  3. IRCCS Santa Lucia, Rome, Italy

    Alessandro Stefani

  4. IRCCS Neuromed, Pozzilli, Italy

    Orazio Schillaci

Authors
  1. Agostino Chiaravalloti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Stefani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Fiorentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annamaria Lacanfora
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paolo Stanzione
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Orazio Schillaci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agostino Chiaravalloti.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chiaravalloti, A., Stefani, A., Fiorentini, A. et al. Do CSF levels of t-Tau, p-Tau and β1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease. Eur J Nucl Med Mol Imaging 41, 2137–2143 (2014). https://doi.org/10.1007/s00259-014-2841-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-014-2841-4

Keywords

Search

Navigation